## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.4% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Daiwa Securities Group Inc. Raises Stock Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251210T100906 | Bullish | Relevance: 99%
- Daiwa Securities Group Inc. increased its stake in Medtronic PLC by 13.0% during the second quarter, bringing its total holdings to 288,201 shares valued at approximately $25.12 million. This move aligns with a supportive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $110.44. Medtronic recently exceeded quarterly earnings estimates and declared a quarterly dividend of $0.71 per share.

**2. Medtronic plc announces successful early commercial use of Liberant thrombectomy system**
- Source: marketscreener.com | 20251210T200835 | Bullish | Relevance: 99%
-  Medtronic plc has announced the successful early commercial use of its Liberant thrombectomy system. The news was published on December 10, 2025, at 02:11 pm EST. The article also provides details on Medtronic's stock performance, company profile, and analyst ratings.

**3. Medtronic Announces FDA Clearance of Hugo Robotic-Assisted Surgery System for Urologic Surgical Procedures**
- Source: Oncodaily | 20251210T182515 | Bullish | Relevance: 99%
-  Medtronic (NYSE: MDT) has announced that its Hugo robotic-assisted surgery (RAS) system has received FDA clearance for urologic surgical procedures in the U.S. This clearance introduces a versatile robotic platform designed to expand soft-tissue robotic surgery programs and enhance access to minimally invasive care. The Hugo RAS system features a modular design, seamless integration with the Touch Surgery ecosystem for training and insights, and is supported by Medtronic's comprehensive surgical offerings.

**4. Medtronic PLC $MDT Position Raised by Marshall Wace LLP**
- Source: MarketBeat | 20251210T115141 | Bullish | Relevance: 98%
-  Marshall Wace LLP significantly increased its stake in Medtronic PLC by 3,424.7% in the second quarter, now owning 160,374 shares worth $13.98 million. Other institutional investors also adjusted their holdings in the medical technology company, which reported strong Q2 earnings, surpassing analyst estimates. Medtronic also announced a quarterly dividend of $0.71 per share, payable on January 16th.

**5. Medtronic PLC $MDT is EDENTREE ASSET MANAGEMENT Ltd's 3rd Largest Position**
- Source: MarketBeat | 20251211T094829 | Somewhat-Bullish | Relevance: 98%
-  EDENTREE ASSET MANAGEMENT Ltd has reduced its stake in Medtronic PLC (NYSE:MDT) by 12.9% in the second quarter, making it their third-largest holding. Despite this reduction, Medtronic constitutes approximately 5.1% of EDENTREE ASSET MANAGEMENT Ltd's investment portfolio, valued at $18,513,000. Other institutional investors have also adjusted their positions in Medtronic, with the company reporting strong financial performance and analyst price targets.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $127.9B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 5.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.53), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.37% (CS: 13) | Weak |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 1.096x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.75
- **Stop Loss:** $96.07 (3.7% risk)
- **Target:** $103.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 374
- **Position Value:** $37,306.50
- **Portfolio %:** 37.31%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*